Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Abstract excerpt

BACKGROUND: Parkinson's disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Parkinson's disease, but drug discovery is challenged by lack of in vivo models that recapitulate early stages of neurodegeneration. Invertebrate organisms, such as the nematode worm Caenorhabditis...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetics, Aging, and Longevity in Model Organisms
• Share to Parkinson's Disease Mechanisms and Treatments
• Share to Sirtuins and Resveratrol in Medicine